Improving combination cancer therapy: the CombiPlex® development platform

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

(2017) Max J. Gordon et al.   LEUKEMIA RESEARCH

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

(2016) Sariah Liu et al.   Oncotarget

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

(2015) Lene Sofie Granfeldt Østgård et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

(2014) J. E. Lancet et al.   BLOOD

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

(2014) Jorge E. Cortes et al.   CANCER

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

(2014) A. W. Tolcher et al.   CLINICAL CANCER RESEARCH

A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma

(2013) Lauren C. Harshman et al.   Clinical Genitourinary Cancer

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

(2013) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study

(2012) Edwin A. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

(2012) E.J. Feldman et al.   LEUKEMIA RESEARCH

Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells

(2011) Hyun Pyo Kim et al.   EXPERIMENTAL HEMATOLOGY

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2011) Eric J. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin

(2010) Awa Dicko et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

(2010) Wah-Seng Lim et al.   LEUKEMIA RESEARCH

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

(2009) G. Batist et al.   CLINICAL CANCER RESEARCH

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

(2009) P. G. Tardi et al.   MOLECULAR CANCER THERAPEUTICS

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of CPX-351 (Cytarabine/Daunorubicin HCl) Liposome injection in the mouse

(2008) William F. Bayne et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

(2008) Paul Tardi et al.   LEUKEMIA RESEARCH